Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

OSAHS Screening in Diverse Populations

26 juli 2026 bijgewerkt door: Kang Wu

Screening for Obstructive Sleep Apnea-hypopnea Syndrome - for Community Populations, Patients With Specific Diseases and Special Populations

The goal of this prospective observational study is to learn about the current prevalence of obstructive sleep apnea-hypopnea syndrome in community population, patients with specific diseases and special population from China. The main question it aims to answer is: (1) What are the prevalence and clinical characteristics of OSA in the community population, the specific disease population and the special population respectively? (2) How about the application value of each OSA screening questionnaire for different populations？Participants will all complete a screening questionnaire, and some will be selected by random sampling to complete either a polysomnography (PSG) or a portable sleep monitor (PM).

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

  1. This is a multi-center study spans China, engaging many hospitals and research institutions. It involves community residents, patients with hypertension, COPD, and other specific diseases, as well as special populations like university teachers and students, and company employees. The study is still recruiting and 2,185 subjects have been included currently.
  2. This study employs rigorous randomization methods to ensure the representativeness of the sample and the reliability of the results. For community residents, cluster sampling is first applied. A random number table method is used to select several communities within the designated research area. The research team then obtains a complete list of registered residents in these communities as the sampling frame. A computer-based random number generator is utilized to randomly select target residents. Those selected are contacted by telephone for the screening questionnaire. If telephone contact fails, interviewers visit the residents' homes to conduct the survey, ensuring every selected resident has an equal chance of participation.
  3. For individuals categorized into OSA high - risk and low - risk groups based on the screening questionnaire, computer - based numbering and randomization are used. Specifically, the information of individuals in each group is entered into a computer system, which assigns a unique number to each individual. Random number - generation software then produces a random sequence of numbers. Individuals are selected for subsequent PSG or PM based on this sequence. This method ensures the scientific and unbiased selection of the sample.
  4. The sample size is determined based on OSA's expected prevalence (23.6%). To estimate the 95% confidence interval with a 5% precision level, at least 277 participants are needed for diagnostic monitoring. Considering a 30% dropout rate and an 80% response rate for the screening questionnaire, the total sample size is set at 100,000 for questionnaires and 10,000 for PSG or PM.
  5. Missing data will be handled through multiple imputation. The reasons for missing data are recorded, and sensitivity analyses assess its impact on results. Data checks verify that entries meet predefined rules for range and consistency, identifying and correcting anomalies promptly.
  6. SOPs cover all aspects of registry operations, ensuring consistency and quality in data collection and management. All questionnaires were manually entered into the electronic system. The reports of PSG or PM were manually interpreted by two professional sleep physicians. In case of disputes, a third person was invited to intervene.

Studietype

Observationeel

Inschrijving (Geschat)

100000

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Donghao Wang, Phd
  • Telefoonnummer: +86 15622204731
  • E-mail: 820512548@qq.com

Studie Contact Back-up

Studie Locaties

  • China
    • Guangdong
      • Guangzhou, Guangdong, China
        • Werving
        • The First Affiliated Hospital of Guangzhou Medical University
        • Contact:
    • Guizhou
      • Anshun, Guizhou, China
        • Nog niet aan het werven
        • Anshun People's Hospital
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Bemonsteringsmethode

Kanssteekproef

Studie Bevolking

Target participants were recruited from multiple centers:

Community population: A random number table method is used to select several communities within the designated research area. The research team then obtains a complete list of registered residents in these communities as the sampling frame. A computer-based random number generator is utilized to randomly select target residents.

Patients with specific diseases: hypertension, diabetes, cardiovascular and cerebrovascular diseases, chronic obstructive pulmonary disease, asthma and other OSA related comorbidities.

Special population: Including college teachers and students, doctors and nurses, and company employees.

Beschrijving

Inclusion Criteria:

  • Sign the informed consent form before participating in the study
  • Complete independent behaviour and cognitive abilities
  • Ability to answer the questionnaire completely and accurately

Exclusion Criteria:

  • Incomplete answers to the scale
  • Patients with severe diseases and acute infections or those requiring long-term home oxygen therapy
  • Patients with severe mental and psychological disorders
  • Patients with severe organ failure
  • patients with a total sleep time <240 min by PSG or PM

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
community population
registered community populations aged 18-80 years old.
patients with specific diseases
patients with hypertension, diabetes, cardiovascular and cerebrovascular diseases, chronic obstructive pulmonary disease, asthma and other OSA related comorbidities, aged 18-80 years old.
Ander: patients with hypertension, diabetes, cardiovascular and cerebrovascular diseases, chronic obstructive pulmonary disease, asthma and other OSA related comorbidities.
In order to explore the prevalence of OSA in patients with different comorbid diseases, this study set up this observation group.
special population
Including college teachers and students, doctors and nurses, and company employees, aged 18-80 years old.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Apnea-Hypopnea Index (AHI)
Tijdsspanne: Baseline
Collected from polysomnography (PSG) or home sleep apnea testing (PM) for the diagnosis of obstructive sleep apnea (OSA). Unit of Measure: events/hour
Baseline
Lowest Oxygen Saturation (Lowest SpO₂)
Tijdsspanne: Baseline
Collected from PSG or PM to evaluate nocturnal hypoxemia. Unit of Measure: %
Baseline

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Diagnostic Value of the CNCQ-OSA Questionnaire
Tijdsspanne: Baseline
Based on the PSG/PM results as the reference standard, the diagnostic accuracy of the Obstructive Sleep Apnea Screening Questionnaire for Chinese Community (CNCQ-OSA) will be evaluated. The outcome measures include sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy rate. Unit of Measure: %
Baseline
Diagnostic Value of the STOP-Bang Questionnaire
Tijdsspanne: Baseline
Based on the PSG/PM results as the reference standard, the diagnostic accuracy of the STOP-Bang questionnaire will be evaluated. The outcome measures include sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy rate. Unit of Measure: %
Baseline
Diagnostic Value of the NoSAS Score
Tijdsspanne: Baseline
Based on the PSG/PM results as the reference standard, the diagnostic accuracy of the Neck circumference, Obesity, Snoring, Age, Sex (NoSAS) score will be evaluated. The outcome measures include sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy rate. Unit of Measure: %
Baseline

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Kang Wu

Onderzoekers

  • Studie directeur: Nuofu Zhang, professor, The First Affiliated Hospital of Guangzhou Medical University

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 september 2024

Primaire voltooiing (Geschat)

1 augustus 2027

Studie voltooiing (Geschat)

1 augustus 2027

Studieregistratiedata

Eerst ingediend

6 juni 2025

Eerst ingediend dat voldeed aan de QC-criteria

26 juli 2026

Eerst geplaatst (Werkelijk)

30 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

26 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • ES-2024-169-01
  • 202201020586 (Ander subsidie-/financieringsnummer: Guangzhou Science and Technology Bureau)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

all IPD that underlie results in a publication

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • MVO

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren